

**In the Claims**

Please replace all prior versions, and listings, of claims in the application with the following list of claims:

1. (Currently Amended) A method for inducing apoptosis in a tumor cell, comprising:  
contacting a tumor cell with an amount of a metabolic modifying agent, which when exposed to a cell causes coupling of electron transport and oxidative phosphorylation, effective to increase the mitochondrial membrane potential in the tumor cell, wherein the metabolic modifying agent is selected from the group consisting of glucose, an MHC class II HLA-DP/DQ ligand, guanosine diphosphate (GDP), sodium acetate, and a combination of phorbol myristate acetate in combination with and ionomycin, ~~GDP, sodium acetate, UCP antisense, dominant negative UCP, and staurosporine,~~ and  
contacting the tumor cell with an amount of an apoptotic chemotherapeutic agent effective for inducing apoptosis in the tumor cell, wherein the apoptotic chemotherapeutic agent is selected from the group consisting of methotrexate, 5-fluorouracil, floxuridine, cytarabine, azauridine, Interferon  $\alpha$ , cisplatin, carboplatin, TAXOL™, and ADRIAMYCIN™.
2. (Currently Amended) The method of claim 1, wherein the apoptotic chemotherapeutic agent is selected from the group consisting of ADRIAMYCIN™, cytarabine, ~~doxorubicin,~~ and methotrexate.
3. (Original) The method of claim 1, wherein the metabolic modifying agent and the apoptotic chemotherapeutic agent are administered simultaneously.
4. (Original) The method of claim 1, wherein the metabolic modifying agent and the apoptotic chemotherapeutic agent are administered locally.

5. (Original) The method of claim 1, wherein the tumor cell is resistant to the apoptotic chemotherapeutic agent.

6. (Currently Amended) A method for inducing apoptosis in a tumor cell, comprising:  
contacting a tumor cell with an amount of a metabolic modifying agent, which when  
exposed to a cell causes coupling of electron transport and oxidative phosphorylation, effective to  
increase the mitochondrial membrane potential in the tumor cell, wherein the metabolic modifying  
agent is selected from the group consisting of glucose, an MHC class II HLA-DP/DQ ligand,  
guanosine diphosphate (GDP), sodium acetate, and a combination of phorbol myristate acetate and  
ionomycin, and staurosporine, and  
contacting the tumor cell with an amount of an apoptotic chemotherapeutic agent  
selected from the group consisting of methotrexate, pyrimidine analogs, purine analogs, cisplatin,  
carboplatin, TAXOL™, and tamoxifen effective for inducing apoptosis in the tumor cell The  
method of claim 1, wherein the tumor cell is sensitive to the apoptotic chemotherapeutic agent, and  
wherein the amount of metabolic modifying agent is effective to increase mitochondrial membrane  
potential and the amount of apoptotic chemotherapeutic agent is effective to inhibit the proliferation  
of the tumor cell when the mitochondrial membrane potential is increased.

7. (Currently Amended) A method for inducing apoptosis in a tumor cell, comprising:  
contacting a tumor cell with an amount of a metabolic modifying agent, which when  
exposed to a cell causes coupling of electron transport and oxidative phosphorylation, effective to  
increase the mitochondrial membrane potential in the tumor cell, and  
contacting the tumor cell with an amount of an apoptotic chemotherapeutic agent  
effective for inducing apoptosis in the tumor cell, wherein the apoptotic chemotherapeutic agent is  
selected from the group consisting of cytarabine, ~~doxorubicin~~, and methotrexate.

8. (Currently Amended) The method of claim 7, wherein the metabolic modifying agent  
is selected from the group consisting of glucose, an MHC class II HLA-DP/DQ ligand, ~~phorbol~~

~~myristate acetate in combination with ionomycin~~, GDP, sodium acetate, UCP antisense, dominant negative UCP, ~~and staurosporine~~ and a combination of phorbol myristate acetate with ionomycin.

9. (Original) The method of claim 7, wherein the metabolic modifying agent and the apoptotic chemotherapeutic agent are administered simultaneously.

10. (Original) The method of claim 7, wherein the metabolic modifying agent and the apoptotic chemotherapeutic agent are administered locally.

11. (Original) The method of claim 7, wherein the tumor cell is resistant to the apoptotic chemotherapeutic agent.